Effect of dihydrofolate reductase inhibitors on experimental cutaneous leishmaniasis, with especial emphasis on Leishmania isolates from Latin-America.
D000818:Animals; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D002489:Central America; D006224:Cricetinae; D004352:Drug Resistance, Microbial; D005069:Evaluation Studies as Topic; D005493:Folic Acid Antagonists; D006801:Humans; D007896:Leishmaniasis / Q000188:drug therapy*; D008800:Mexico; D051379:Mice; D011739:Pyrimethamine / Q000627:therapeutic use; D013020:South America; D013411:Sulfadiazine / Q000627:therapeutic use; D014295:Trimethoprim / Q000627:therapeutic use
D000981:Antiprotozoal Agents; D005493:Folic Acid Antagonists; D013411:Sulfadiazine; D014295:Trimethoprim; D011739:Pyrimethamine